Market Revenue Cystic Fibrosis (CF) Therapeutics Industry

Pricing will be premium for CFTR modulators due to the therapeutic benefits. Symptomatic therapies will continue to be a necessary part in conjunction with CFTR modules. Comparatively, the antibiotics segment is expected to gain second importance owing to the competitiveness and novel market entrants. A multi-resistant superbug infection that can prove fatal for patients suffering from cystic fibrosis (CF) has spread globally and is becoming viral, according to the British researchers. Moreover, it has not only gone viral but is evolved and capable to jump from patient to patient, according Andres Floto, a Cambridge University professor. Adding further, he said that as the superbug has become resistant to various antibiotics; it is also difficult to treat it successfully. As a part of treatment infected patients may need more than a year of treatment with a combination of strong antibiotics and the ratio of cure is one in three. The market is segmented on the basis of geography which includes North America, Europe, Asia-Pacific, Middle- east and Africa. The European region dominates the global market scenario and is considered as the most fertile market which is also followed by North America. Asia-pacific regions are considered to be the least important market owing to less prevalence of the disorder. The key players include Novartis International AG, Chiesi Farmaceutici SpA, Vertex Pharmaceuticals, Genentech, Inc., and Gilead Sciences, Inc. Vertex Pharmaceuticals is the developer of kalydeco and expected to be a key player in the global market. Browse Full Research Report @ https://www.millioninsights.com/industry-reports/cystic-fibrosis-cf-therapeutics-market Market Segmentation Cystic Fibrosis Therapeutics Drug Class Outlook (Revenue, USD Million, 2014 - 2025) • Pancreatic enzyme supplements • Mucolytics • Bronchodilators • CFTR modulators Cystic Fibrosis Therapeutics Route of Administration Outlook (Revenue, USD Million, 2014 - 2025) • Oral drugs • Inhaled drugs Cystic Fibrosis Therapeutics Regional Outlook (Revenue, USD Million, 2014 - 2025) • North America • U.S. • Canada

Market Revenue Cystic Fibrosis (CF) Therapeutics Industry | Page 2